Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Organ transplantation is a procedure, wherein a healthy organ is transferred from a living or deceased body into another individual’s body. It is the primary treatment option for an end-stage organ failure. The process can also involve transplantation of more than one organ at a time. Demand for organ transplant immunosuppressant drugs is rising due to increase in the number of people registering for organ transplant worldwide.

The global organ transplant immunosuppressant drugs market is estimated to be valued at US$ 4,862.0 million in 2021 and is expected to exhibit a CAGR of 3.1 % over the forecast period (2021-2028).

Recent Developments:

In July 2021, the U.S. Food and Drug Administration has approved a new use for Prograf (tacrolimus) based on a non-interventional (observational) study providing real-world evidence (RWE) of effectiveness. FDA approved Prograf for use in combination with other immunosuppressant drugs to prevent organ rejection in adult and pediatric patients receiving lung transplantation. 

In December 2020, Lupin Limited has launched Mycophenolate Mofetil Tablets USP, 500 mg, after Lupin’s alliance partner Concord Biotech Limited (Concord) received an approval for its ANDA from the United States Food and Drug Administration.

In April 2020, Lupin Limited has launched Mycophenolic acid delayed release tablets USP, 180 mg and 360 mg. Mycophenolic acid delayed-release tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic delayed-release tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation, and are indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant and use in combination with cyclosporine and corticosteroids.

North America held dominant position in the global organ transplant immunosuppressant drugs market in 2020, accounting for 46.9% share in terms of volume, followed by Europe and Asia Pacific, respectively. Dominance of North America region can be attributed to growing organ transplantation cases with rising prevalence of chronic diseases, better healthcare infrastructure, and favorable reimbursement scenario. 

Figure 1. Global Organ Transplant Immunosuppressant Drugs Market Value (US$ Mn), by Region, 2020

Organ Transplant Immunosuppressant Drugs  | Coherent Market Insights

Global Organ Transplant Immunosuppressant Drugs Market: Drivers

Increasing incidences of chronic diseases is expected to propel growth of the global organ transplant immunosuppressant drugs market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing geriatric population is also expected to boost demand for organ transplant immunosuppressant drugs. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.         

request-sample

Organ Transplant Immunosuppressant Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 4,734.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 3.1% 2028 Value Projection: US$ 6,007.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Antibodies
  • By Transplant Type: Kidney, Liver, Heart, Lung, Pancreas, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche

Growth Drivers:
  • Increasing incidences of chronic diseases
  • Increasing geriatric population
Restraints & Challenges:
  • High cost of procedure
  • Lack of donor organs

Global Organ Transplant Immunosuppressant Drugs Market: Opportunities 

R&D in organ transplant immunosuppressant drugs is expected to offer lucrative growth opportunities for players in the global organ transplant immunosuppressant drugs market. For instance, in November 2018, Temple University, in collaboration with Veloxis Pharmaceuticals, initiated phase 4 clinical trial for Tacrolimus Extended Release Oral Tablet to evaluate dosing strategies for de novo once-daily extended release tacrolimus (LCPT) in kidney transplant recipients.

Moreover, implementation of favorable reimbursement scenario is also expected to boost demand for organ transplant immunosuppressant drugs. For instance, in January 2020, The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 (HR 5534) extended Medicare coverage of immunosuppressive drugs for kidney transplants past the 36-month cut-off currently in place to cover the medications for the life of the transplant.

Market Trends

Increasing mortality among organ transplant patients diagnosed with COVID-19 is expected to propel growth of the global organ transplant immunosuppressant drugs market. For instance, according to the European Renal Association-European Dialysis and Transplant Association, since March 2020, 25% of kidney transplant patients diagnosed with COVID-19 in European countries have died.

The emergence of Covid-19 is expected to have significant impact on heart and lung transplant. For instance, in August 2020, researchers from University Hospital of Siena, Italy, reported that a higher percentage of lung transplant subjected that Covid-19 could have a negative impact on the outcome of their graft. Moreover, 28% of the patients declared that they were afraid to come to the hospital for routine examinations and asked to postpone.

Figure 2. Global Organ Transplant Immunosuppressant Drugs Market Share, By Drug Class, 2020

Organ Transplant Immunosuppressant Drugs  | Coherent Market Insights

Key Takeaways of the Graph:

  • Among Drug Class, the Calcineurin Inhibitors held dominant position in the market and accounted for 35.3% share in the global organ transplant immunosuppressant drugs market in 2020. The segment is expected to reach US$ 2,080.1 million in 2028.
  • Better efficacy of Calcineurin, pipeline studies conducted by different research institutes, and increasing demand of cost effective options are some of the major factors responsible for the dominance of Calcineurin inhibitors segment
  • Among Transplant type, the kidney segment held dominant position in the market and accounted for 53.9% share in the global organ transplant immunosuppressant drugs market in 2020. The segment is expected to reach US$ 3,262.1 million in 2028.
  • Dominance of kidney segment during the forecast period can be attributed to increasing kidney transplantation, growing demand of immunosuppressant drugs, and accessibility of large number of drug options for kidney transplant immunosuppressant

Global Organ Transplant Immunosuppressant Drugs Market: Restraints

High cost of procedure is expected to hinder growth of the global organ transplant immunosuppressant drugs market. Patient non-adherence to immunosuppressive medications is related to high medication cost and patient’s inability to pay for the expensive procedures. The cost of post-transplantation care and on-going immunosuppression in several low and middle income countries present a significant barrier to the development of higher transplantation capacity. This has been a driving factor for illegal organ trafficking practiced across the world. Kidney transplant procedure costs around US$ 100,000 in the U.S., US$ 70,000 in China, and only US$ 5,000 in India.

Moreover, lack of donor organs is also expected to hinder growth of the global organ transplant immunosuppressant drugs market. Despite advances in medicine and technology and increased awareness about organ donation and transplantation, the gap between demand and supply continues to widen.

Global Organ Transplant Immunosuppressant Drugs Market: Competitive Landscape

Major player operating in the global organ transplant immunosuppressant drugs market include, Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma AS, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and F-Hoffman La Roche.

Global Organ Transplant Immunosuppressant Drugs Market: Key Developments

Major players in the global organ transplant immunosuppressant drugs market are focused on R&D of new drugs to expand their product portfolio. For instance, in May 2020, TolerogenixX GmbH announced the publication of positive Phase Ib results of its lead product MIC-Lx, a cell therapy product that can induce donor-specific tolerance in kidney transplant recipients, in The Journal of Clinical Investigation.

After a successful organ transplant, you may have to take immunosuppressant drugs. These drugs help your immune system from attacking (rejecting) the new organ from which it has been transplanted. In general, they should be taken for your lifetime, or until the treatments are complete. Orally, or injected into a vein, these drugs work by stopping your body's immune cells from further attacking your transplanted organ. They also control your allergic reactions to the transplanted organ and reduce inflammation around the transplanted tissues.

Market Dynamics:

Approval and launch of new drugs is expected to propel growth of the global organ transplant immunosuppressant drugs market over the forecast period. For instance, in July 2021, Kadmon Holdings, Inc. received the U.S. Food and Drug Administration approval for REZUROCK (belumosudil) for the treatment of adult and pediatric patients with chronic graft-versus-host disease.

Negative outcomes in clinical trials is expected to hinder growth of the global organ transplant immunosuppressant drugs market. For instance, in September 2021, Novartis AG announced to halt a mid-stage clinical trial of drug intended to prevent organ rejection after an early look at data in kidney transplant patients showed the experimental treatment was less effective compared to the standard of care therapy.

The market is witnessing several M&A activities. For instance, in September 2021, Sanofi announced to acquire Kadmon Holdings, a U.S.-based biopharmaceutical company.

Key features of the study:

  • This report provides in-depth analysis of the global organ transplant immunosuppressant drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global organ transplant immunosuppressant drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global organ transplant immunosuppressant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global organ transplant immunosuppressant drugs market

Detailed Segmentation:

  • Global Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
    • Calcineurin Inhibitors
    • Antiproliferative Agents
    • mTOR Inhibitor
    • Steroids
    • Antibodies
  • Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
    • Kidney
    • Liver
    • Heart
    • Lung
    • Pancreas
    • Others
  • Global Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Organ Transplant Immunosuppressant Drugs Market, By Region:
    • North America
      • North America Organ Transplant Immunosuppressant Drugs Market , By Drug Class:
        • Calcineurin Inhibitors
        • Antiproliferative Agents
        • mTOR Inhibitor
        • Steroids
        • Antibodies
      • North America Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
        • Kidney
        • Liver
        • Heart
        • Lung
        • Pancreas
        • Others
      • North America Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • North America Organ Transplant Immunosuppressant Drugs Market , By Country:
        • U.S.
        • Canada
    • Latin America
      • Latin America Organ Transplant Immunosuppressant Drugs Market , By Drug Class:
        • Calcineurin Inhibitors
        • Antiproliferative Agents
        • mTOR Inhibitor
        • Steroids
        • Antibodies
      • Latin America Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
        • Kidney
        • Liver
        • Heart
        • Lung
        • Pancreas
        • Others
      • Latin America Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • Latin America Organ Transplant Immunosuppressant Drugs Market , By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Europe Organ Transplant Immunosuppressant Drugs Market , By Drug Class:
        • Calcineurin Inhibitors
        • Antiproliferative Agents
        • mTOR Inhibitor
        • Steroids
        • Antibodies
      • Europe Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
        • Kidney
        • Liver
        • Heart
        • Lung
        • Pancreas
        • Others
      • Europe Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • Europe Organ Transplant Immunosuppressant Drugs Market , By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Asia Pacific Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
        • Calcineurin Inhibitors
        • Antiproliferative Agents
        • mTOR Inhibitor
        • Steroids
        • Antibodies
      • Asia Pacific Organ Transplant Immunosuppressant Drugs Market , By Transplant Type:
        • Kidney
        • Liver
        • Heart
        • Lung
        • Pancreas
        • Others
      • Asia Pacific Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • Asia Pacific Organ Transplant Immunosuppressant Drugs Market , By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Middle East Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
        • Calcineurin Inhibitors
        • Antiproliferative Agents
        • mTOR Inhibitor
        • Steroids
        • Antibodies
      • Middle East Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
        • Kidney
        • Liver
        • Heart
        • Lung
        • Pancreas
        • Others
      • Middle East Organ Transplant Immunosuppressant Drugs Market , By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • Middle East Organ Transplant Immunosuppressant Drugs Market, By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Africa Organ Transplant Immunosuppressant Drugs Market, By Drug Class:
        • Calcineurin Inhibitors
        • Antiproliferative Agents
        • mTOR Inhibitor
        • Steroids
        • Antibodies
      • Middle East Organ Transplant Immunosuppressant Drugs Market, By Transplant Type:
        • Kidney
        • Liver
        • Heart
        • Lung
        • Pancreas
        • Others
      • Middle East Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • Middle East Organ Transplant Immunosuppressant Drugs Market, By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Astellas Pharma*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategy
    • Genzyme Corporation
    • Accord Healthcare Ltd.
    • Watson Pharmaceuticals, Inc.
    • Novartis AG
    • Mylan Laboratories, Inc.
    • GlaxoSmithKline plc.
    • Belcher Pharmaceuticals LLC
    • Leo Pharma AS
    • Glenmark Pharmaceuticals Ltd.
    • TFF Pharmaceuticals, Inc.
    • TolerogenixX GmbH
    • Veloxis Pharmaceuticals Inc.
    • Reddy’s Laboratories Ltd.
    • Panacea Biotec Ltd.
    • Strides Pharma Global Pte Ltd.
    • F-Hoffman La Roche

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Transplant Type
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Epidemiology
    • Regulatory Scenario
    • Pipeline Analysis
    • PEST Analysis
    • Reimbursement Scenario
  4. Global Organ Transplant Immunosuppressant Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
    • Covid-19 Epidemiology
    • Overall Impact On Countries
    • Key Developments
  5. Global Organ Transplant Immunosuppressant Drugs Market, By Drug Type, 2017 – 2028 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018–2028
      • Segment Trends
    • Calcineurin Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Antiproliferative Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • mTOR Inhibitor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Steroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
  6. Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type, 2017 – 2028 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018–2028
      • Segment Trends
    • Kidney
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Liver
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Heart
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Lung
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Pancreas
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
  7. Global Organ Transplant Immunosuppressant Drugs Market, By Distribution Channel, 2017 – 2028 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018–2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
      • Segment Trends
  8. Global Organ Transplant Immunosuppressant Drugs Market, By Region, 2017 – 2028 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018–2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Transplant Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Transplant Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Transplant Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Transplant Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Transplant Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Transplant Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Company Profiles
      • Astellas Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Genzyme Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Accord Healthcare Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Watson Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mylan Laboratories, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Belcher Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Leo Pharma AS
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Glenmark Pharmaceuticals Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • TFF Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • TolerogenixX GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Veloxis Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Panacea Biotec Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Strides Pharma Global Pte Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F-Hoffman La Roche
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 28 figures on “Organ Transplant Immunosuppressant Drugs Market – Global forecast to 2028.

FAQgrowicon

Frequently Asked Questions

Global organ transplant immunosuppressant drugs market size is estimated to be valued at US$ 4,862.0 Million in 2021 and is expected to exhibit a CAGR of 3.1% between 2021 and 2028.
Increasing incidences of chronic diseases and increasing geriatric population are the factors fueling growth of the market.
The Calcineurin inhibitors segment is the leading drug class segment in the market.
High cost of procedure and lack of donor organs are factors hindering growth of the market.
Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and F-Hoffman La Roche.
North America region is expected to hold dominant position in the market over the forecast period. The growth of the market in the region is driven by favorable healthcare reimbursement policies, and rising demand for organ transplants in the region.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.